linjc16/ctgov huggingface dataset:
A Placebo-Controlled Study Assessing Lateral Branch Radiofrequency Denervation for Sacroiliac (SI) Joint Pain

Study Overview
=================
Brief Summary
-----------------
In order to determine whether L4 and L5 primary dorsal rami and S1-3 lateral branch radiofrequency denervation is effective for sacroiliac (SI) joint pain, we are conducting a randomized, controlled study.

Detailed Description
-----------------
30 subjects with SI joint pain confirmed by SI joint injections will be randomized to receive either L4 and L5 primary dorsal rami and S1-3 lateral branch radiofrequency denervation or sham denervation. To facilitate patient blinding, in both groups 1 ml of lidocaine will be injected before true (or sham) denervation so patients cannot feel heating. The stimulation will be the same for both groups and blinding assessed after the procedure. Follow-up visits will be at 1,3 and 6-months postprocedure.

Conditions
-----------------
Low Back Pain

Intervention / Treatment
-----------------
* Procedure: radiofrequency denervation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sacroiliac joint pain Age > 18 Exclusion Criteria: No focal neurological signs or symptoms, coagulopathy, unstable medical or psychiatric condition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: radiofrequency denervation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual analogue scale pain score, Oswestry Disability Index |  | 1, 3 and 6 months postprocedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Medication reduction, global perceived effect, work status |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sacroiliac joint, low back pain, radiofrequency
Effectiveness of Spot-on ™ to Prevent Inadvertent Perioperative Hypothermia and Their Consecuences

Study Overview
=================
Brief Summary
-----------------
Using the spot-on device for monitoring core body temperature during colon laparoscopic surgery and prevent non-therapeutic hypothermia.

Detailed Description
-----------------
Take active measures to prevent non-therapeutic hypothermia during the laparoscopic colon surgery. We improve these measures using heat conductive air warm blankets placed under and o over the patient. Perform monitoring core body temperature every 15 minutes by spot-on device compared with standard nasopharyngeal probe.

Official Title
-----------------
Effectiveness of Spot-on ™ to Prevent Inadvertent Perioperative Hypothermia and Their Consecuences

Conditions
-----------------
Hypothermia

Intervention / Treatment
-----------------
* Device: Spot-On


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients that need a colorrectal laparoscopic surgery Exclusion Criteria: Use of antagonist of Calcium Alergy to medications History of Malignant Hipertemia Laparosocopy surgery ≥ 120 min Temperature previous surgery over 38ºC Taking chronic steroids

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Spot-on group<br>Use active measures against intraoperative hypothermia | Device: Spot-On<br>* use of active hot measures<br>|
| No Intervention: control<br>standard measures against intraoperative hipothermia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in the Body Core Temperature | measure the body core temperature by Spoton device when the patient arrive to operating room | measure every 15 minutes since the patient arrive to operating room until is derivated to recovery room, an average of 3 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of blood transfusion | Transfusion if hemoglobin lower than 7 mgr/dl | In the first two weeks after being operated. | 
| surgical wound infection | the surgeon determines the infection of the surgical wound | while the patient stay in the hospital, an average of two weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spot-on; perioperative hypothermia.
Non-contrast 3D MR Angiography for Assessment of the Thoracic Aorta in Pregnancy

Study Overview
=================
Brief Summary
-----------------
Introduction: Native magnetic resonance angiography (MRA) is recommended to assess the thoracic aorta during pregnancy, avoiding the risks of ionising radiation and contrast agent administration. This guidance is however, based only on consensus opinion supported by limited case reports (level of evidence C). Aim: To evaluate the feasibility of performing native 3D steady-state free-precession (SSFP) MRA in pregnant subjects with inherited aortopathy to guide timing and mode of delivery.

Official Title
-----------------
Native High-resolution 3D SSFP MR Angiography for Assessment of the Thoracic Aorta in Pregnant Subjects With Familial Aortopathies

Conditions
-----------------
Magnetic Resonance Imaging, Pregnancy

Intervention / Treatment
-----------------
* Other: observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any pregnant subject with a history of familial aortopathy Exclusion Criteria: None
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: observational|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gestation at delivery |  | 40 weeks | 
| Completion of non-contrast 3D MRA aorta |  | 40 weeks |
Verification of the Quantitative Accuracy of the PET/CT System Imaging Chain

Study Overview
=================
Brief Summary
-----------------
The purpose of this study will evaluate new technologies that have been included in the new PCA-9000A PET/CT System.

Detailed Description
-----------------
Scope: To evaluate the new technologies that have been included in the PCA-9000A PET/CT System, the study has the following 3 goals. Define and confirm all supported clinical protocols from Low-Dose CT, to PET acquisition and presentation. Verification of the quantitative accuracy of the imaging chain. Evaluate the performance and stability of the new system and its related quality control and calibration procedures. Result (Expected): The study is an essential step in assessing the quality of the hardware and software defining the new PCA-9000A PET/CT System. Several essential parameters for the acquisition, reconstruction, correction, filtering, and presentation will be estimated or adjusted during this period. The evaluation will confirm PCA-9000A PET/CT System is effective for its intended use.

Official Title
-----------------
ROMAN (PCA-9000A) PET/CT System Verification

Conditions
-----------------
Confirm PCA-9000A PET/CT System is Effective for Its Intended Use

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Patients already scheduled for an FDG test at SDMI 40 years and older Adult must be able to sign an informed consent form Exclusion Patients not scheduled for an FDG test at SDMI 39 years or younger Pregnant adult female or plan to be pregnant Adult who is unable to sign the informed consent

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids

Study Overview
=================
Brief Summary
-----------------
This research study helps to demonstrate that adding vitamins and fats (nutritional supplements) to a diet will help reduce body weight and improve the lipid profile. This will be done by examining the body weight and chemicals in the blood. The chemicals are the result of the brain using the fat that subjects eat in their diet. Some medications may also change the amount of these chemicals in a person's blood.

Detailed Description
-----------------
To demonstrate that supplementation of antioxidants and omega-3 fatty acids will improve clinical outcome including cognitive performance in olanzapine treated patients.

Official Title
-----------------
Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: Olanzapine, Omega 3, Vitamin E+C


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 to 55 VA outpatient Diagnosis of schizophrenia by DSM-IV criteria Active treatment with olanzapine Medically healthy Exclusion Criteria: Diagnosis of MR MMSE score of < 26 Not on a stable dose of olanzapine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Olanzapine<br> | Drug: Olanzapine, Omega 3, Vitamin E+C<br>* No adverse event nor SAE noted.<br>|
| Active Comparator: Omega 3<br> | Drug: Olanzapine, Omega 3, Vitamin E+C<br>* No adverse event nor SAE noted.<br>|
| Active Comparator: Vitamin E +C<br> | Drug: Olanzapine, Omega 3, Vitamin E+C<br>* No adverse event nor SAE noted.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PANSS | Study completed in 2006. PI no longer with the institution. Study was closed accordingly to the HAC. | 2003-2006 | 
| BMI | BMI match height and weight. | 2003-2006 | 
| Blood samples | Samples analyzed, PI analyzed and published. PI no longer with the institution. | 2003-2006 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive assessments | BACS assessment. Data analyzed and published by the PI. | 2003-2006 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
weight gain, weight gain supplementation, antioxidants, olanzapine
Air Tamponade in Macular Hole Surgery

Study Overview
=================
Brief Summary
-----------------
Macular hole is a hole formation which takes place in the center of the retina. Such a hole needs surgical steps in order to close. Closure of the macular hole will lead to a substantially improvement of vision in most cases. Following macular hole surgery a tamponade of intraocular gas is normally injected in order to keep the macula dry for the postoperative period. Postoperative face down position for a week was earlier standard. Several authors report of good closure rates with both air tamponade or lack of face down positioning. In this study standard pars plana vitrectomy with peeling of the internal limiting membrane (ILM) will be performed. The gas tamponade will be replaced by air. Postoperative face down positioning will not be used.

Official Title
-----------------
Air Tamponade in Macular Hole Surgery

Conditions
-----------------
Macular Hole

Intervention / Treatment
-----------------
* Procedure: Pars plana vitrectomy and postoperative air tamponade


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Idiopathic stage 2 - 4 macular hole Duration of symptoms ≤ 36 months Informed consent Exclusion Criteria: Previous vitreomacular surgery Myopia ≥ 6 diopters Ocular trauma Disease affecting visual function
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pars plana vitrectomy and postoperative air tamponade<br>Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention. | Procedure: Pars plana vitrectomy and postoperative air tamponade<br>* Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Closure rate of macular hole |  | 1 month after enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Closure rate in macular holes larger than 400 micrometer |  | 1 month after enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Macular hole, Vitreoretinal surgery, Macular surgery, Air tamponade
Digital Mammography: Computer-Aided Breast Cancer Diagnosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to develop computer programs to assist radiologists in finding breast cancer on mammograms and to compare the computer's accuracy of detecting cancers on direct digital and film mammograms.

Detailed Description
-----------------
To develop a computer-aided diagnosis (CAD) system for full field digital mammography (FFDM) using advanced computer vision techniques and to evaluate the effects of CAD on interpretation of digital mammograms (DMs). This system will assist radiologists with the four most important areas in mammographic interpretation: (1) detection of masses, (2) classification of masses, (3) detection of microcalcifications, (4) classification of microcalcifications. The proposed approach is distinctly different from previous approaches in that image information from two-view and bilateral mammograms will be fused with that from the single-view mammogram to improve lesion detection and characterization.

Official Title
-----------------
Digital Mammography: Computer-Aided Breast Cancer Diagnosis

Conditions
-----------------
Tumors, Breast

Intervention / Treatment
-----------------
* Procedure: digital mammography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females who have been scheduled for mammographic exams. Females who have been recommended for work-up or biopsy due to a suspicious finding on their mammogram. Females who can give informed consent. Exclusion Criteria: No subject under 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: digital mammogram<br>Digital mammography is a non-invasive imaging technique to obtain an x-ray image of the breast. Two-view digital mammogram of the breast with a lesion that has been recommended for biopsy during the subject's regular clinical care. The digital mammogram is then analyzed by a computer program. | Procedure: digital mammography<br>* Using non-invasive digital mammography with computer aided programs to screen, detect and characterize breast lesions/cancer.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Using computer aided programs to assist in detection and characterization of breast lesions in digital mammography. |  | Research scan will be completed at the time of scheduled clinical visit. |
Robotic Decompression of the Pudendal Nerve in Pudendal Neuralgia

Study Overview
=================
Brief Summary
-----------------
Primary purpose: Show the pain improvement 3-month after robotic laparoscopic pudendal nerve decompression for pudendal neuralgia. Primary outcomes: Pain evaluated on a VAS before surgery and 3-month after surgery or surveillance Improvement is considered if pain decreased by at least 3/10 points on the VAS. Secondary purposes: improvement of quality of life study of MRI performance to predict pudendal nerve entrapment topography show the feasibility and safety of robotic pudendal nerve decompression

Official Title
-----------------
Robotic Decompression of the Pudendal Nerve in Pudendal Neuralgia: A Randomized Controlled Trial

Conditions
-----------------
Robotic Decompression

Intervention / Treatment
-----------------
* Procedure: Robotic laparoscopic decompression of pudendal nerve entrapment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 - 70 years old Pudendal neuralgia according to Nantes criteria pudendal nerve entrapment reachable with robotic transperitoneal approach Exclusion Criteria: bilateral pain history of pain ≥ 18 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Non-invasive<br>Neuropathic drugs Pudendal infiltration | |
| Experimental: Robotic laparoscopic decompression<br>Robotic laparoscopic decompression of pudendal nerve entrapment. | Procedure: Robotic laparoscopic decompression of pudendal nerve entrapment<br>* Robotic laparoscopic decompression of pudendal nerve entrapment. Transperitoneal Laparoscopic Robotic assistance<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of the maximum pain intensity on a numerical scale (EN), calculated on 10 points. (0 no pain -10 extreme pain ) | Collection of the maximum pain intensity on a numerical scale (EN), calculated on 10 points. Daily collection by the patient over 1 week in real life conditions. Achievement of an average of the scores over 1 week. | 3-months after surgery or surveillance |
Prevalence of Electrolyte Imbalance in Chronic Kidney Disease:A Study at Tertiary Care Hospital in South Punjab,Pakistan

Study Overview
=================
Brief Summary
-----------------
an observational cross-sectional study is done to calculate the electrolyte imbalance at different stages of chronic kidney disease at tertiary care hospital.

Detailed Description
-----------------
an observational cross-sectional study is done to calculate the electrolyte imbalance at different stages of chronic kidney disease at tertiary care hospitals of south Punjab, Pakistan .The outcomes of chronic kidney disease and end stage of renal failure will be calculated according to standard protocol. Under the supervision of pathologists, pharmacologists, pharmacists, nephrologists, urologists and biostatistician. The standard protocol was authorized by ethical committee of each center. patient consent form was

Official Title
-----------------
Prevalence of Electrolyte Imbalance in Chronic Kidney Disease: A Study at Tertiary Care Hospitals in South Punjab, Pakistan

Conditions
-----------------
Chronic Kidney Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CKD patients ranging age from 20-80 dialysis and pre-dialysis patients who provide written consent form Exclusion Criteria: congenital one kidney patients organ or kidney donors and transplantation pregnant women renal injury during trauma

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients of chronic kidney disease<br>no interventions | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum potassium in mEq/L | Serum potassium in mEq/L by taking blood sample under standard condition | 2days | 
| serum urea in mg/dl | serum urea in mg/dl by taking blood sample under standard condition | 2days | 
| Serum creatinine in mg/dl | Serum creatinine in mg/dl by taking blood sample under standard condition | 2days | 
| Serum calcium in mg/dl | Serum calcium in mg/dl by taking blood sample under standard condition | 2days | 
| Serum sodium in mEq/L | Serum sodium in mEq/L by taking blood sample under standard condition | 2days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure in mm of Hg | Blood pressure in mm of Hg | 2days | 
| Blood glucose concentration in mg/dl | Blood glucose concentration in mg/dl random | 2days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CKD